BioCentury | Dec 28, 2020
Deals

Myovant’s deal with Pfizer for $650M up front is the latest sign women’s health is back

...million.TARGETSGNRHR – GnRH/LHRH receptor Lauren Martz Pfizer Inc. Myovant Sciences GmbH GnRH/LHRH...
BioCentury | Aug 18, 2020
Product Development

Gilead, Tango expand cancer partnership; plus Roche approval, Novavax COVID-19 efficacy study and G1, Myovant and PTC applications under review

...Virtual Launch”).TARGETSAQP4 – Aquaporin-4CDK4 – Cyclin dependent kinase 4CDK6 – Cyclin dependent kinase 6GNRHR – GnRH/LHRH...
BioCentury | Jul 6, 2020
Product Development

July 6 Quick Takes: Cellectis CAR T trial halted; plus data readouts from Bellus, ObsEva, Idorsia, and more

...years (see “Major Multinationals Open, Close, Open R&D Centers in China” ). Targets GNRHR - GnRH/LHRH...
BioCentury | Jun 24, 2020
Regulation

Myovant eyes third NDA for relugolix after endometriosis readout

...under EMA review. Targets GNRHR - GnRH/LHRH receptor Elizabeth S. Eaton, Staff Writer Relumina (relugolix, TAK-385) Myovant Sciences GmbH GnRH/LHRH...
BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

...B gamma BCMA (TNFRSF17; CD269) - Tumor necrosis factor receptor superfamily member 17 GNRHR - GnRH/LHRH...
...plc Myovant Sciences GmbH AbbVie Inc. Assembly Biosciences Inc. Genentech Inc. GlaxoSmithKline plc Innovent Biologics Inc. BeiGene Ltd. Sanofi Regeneron Pharmaceuticals Inc. National Institutes of Health GnRH/LHRH...
BioCentury | Apr 23, 2020
Product Development

April 22 Quick Takes: Accelerated approval for Immunomedics’ Trodelvy; plus BioNTech-Pfizer, AskBio, Astellas, Merck KGaA, oNKo-Gilead, Myovant, Afyx and Sangam

...with uterine fibroids in May 2020. Myovant also submitted an NDA for monotherapy with the GnRH/LHRH...
...Inc. Asklepios BioPharmaceutical Inc. Nanna Therapeutics Ltd. BrainVectis Astellas Pharma Inc. Merck KGaA Afyx Therapeutics BioNTech SE Mogrify Ltd. Immunomedics Inc. Myovant Sciences GmbH Sangamo Therapeutics Inc. GnRH/LHRH...
BioCentury | Mar 23, 2020
Product Development

Lilly trial slowdown could include Phase III GI candidate; Syncona among others acknowledging delays

...fibroids, are fully enrolled; data are due on time next quarter. The therapy is a GnRH/LHRH...
...Outbreak” ). Targets GnRH - Gonadotropin-releasing hormone IL23P19 (IL23A) - Interleukin-23 subunit α LHRH - Luteinizing hormone-releasing hormone Paul...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

...zeste homolog 2 (EZH2) Fibroblast activation protein (FAP) Folate receptor 1 (FOLR1) (FR-alpha) (FOLR) Ganglioside GD2 (GD2) Glypican 2 (GPC2) GnRH/LHRH...
BioCentury | Sep 6, 2019
Company News

Sumitomo Dainippon to bolster pipeline via deal for women's health, urology, rare disease vants for $3B

...$673 million, after shedding $0.53 to $7.51 on Friday. Its lead program is relugolix, a GnRH/LHRH...
...Pharmaceutical Co. Ltd. Urovant Sciences Ltd. Datavant Inc. Sumitomo Dainippon Pharma Co. Ltd. Roivant Sciences Ltd. Adrenergic receptor beta 3 (ADRB3) GnRH/LHRH...
BioCentury | Jul 23, 2019
Clinical News

July 23 Clinical Quick Takes: Achillion plans U.S. IND; plus Chiasma, Myovant, Marinus and Merck

...uterine fibroids. The company plans to submit an NDA to FDA by YE19 for the GnRH/LHRH...
...Pharmaceuticals Inc. Chiasma Inc. Marinus Pharmaceuticals Inc. Merck & Co. Inc. Myovant Sciences GmbH Complement factor D (CFD) (adipsin) GABA A receptor GnRH/LHRH...
Items per page:
1 - 10 of 495